Sanctuary Advisors’s Summit Therapeutics SMMT Stock Holding History

Sanctuary Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,244	Closed	-$282K	–	2537
2025 Q2	$282K	Buy	+13,244	New	+$302K	﹤0.01%	1964

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

ACL

APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Sanctuary Advisors's SMMT Position: Q3 2025 in Review

Sanctuary Advisors sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 13,244 shares — an estimated $282K sold.

Sanctuary Advisors first reported a position in SMMT in Q2 2025 and held it in 1 quarter. The position peaked at $282K in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

Sanctuary Advisors reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
Sanctuary Advisors sold 13,244 Summit Therapeutics shares in Q3 2025, an estimated $282K.
Sanctuary Advisors first reported a position in Summit Therapeutics in Q2 2025 and held it in 1 quarter.
Sanctuary Advisors's Summit Therapeutics position peaked at $282K in Q2 2025.
232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Sanctuary Advisors's 13F filing for Q3 2025, filed 6 Jan 2026.